1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 4.1. Market Research Process 4.2. Research Design 4.3. Research Methodology 5. Scope of the Report 5.1. Market Overview 5.2. Product Offerings 6. Market Landscape 6.1. Global Cephalosporin Drugs Market 6.1.1. Market Size and Forecast 7. Five Force Analysis 8. Geographical Segmentation 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 16.1. Pfizer Inc. 16.1.1. Business Overview 16.1.2. Key Information 16.1.3. SWOT Analysis 16.2. Cubist Pharmaceuticals Inc. 16.2.1. Business Overview 16.2.2. Key Information 16.2.3. SWOT Analysis 16.3. ViroPharma Inc. 16.3.1. Business Overview 16.3.2. Key Information 16.3.3. SWOT Analysis 16.4. Forest Laboratories Inc. 16.4.1. Business Overview 16.4.2. Key Information 16.4.3. SWOT Analysis 16.5. Theravance Inc. 16.5.1. Business Overview 16.5.2. Key Information 16.5.3. SWOT Analysis 17. Other Reports in this Series List of Exhibits: Exhibit 1: Market Research Methodology Exhibit 2: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs 2012-2016 (US$ millions) Exhibit 3: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market by Geographical Segmentation 2012 Exhibit 4: Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market by Vendor Segmentation 2012

Pfizer Inc., Cubist Pharmaceuticals Inc., ViroPharma Inc., Theravance Inc., Forest Laboratories Inc., Basilea Pharmaceutica Ltd., Durata Therapeutics, Inc., Novartis AG, Trius Therapeutics, Inc., AstraZeneca plc., and GlaxoSmithKline plc.